Get the Stockscreener App
259.27
0.23%
-0.656
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $259.27, with a volume of 594.49K.
It is down -0.23% in the last 24 hours and down -0.91% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$259.93
Open:
$259.74
24h Volume:
594.49K
Relative Volume:
0.12
Market Cap:
$458.42B
Revenue:
$62.82B
Net Income/Loss:
$3.60B
P/E Ratio:
127.88
EPS:
2.0274
Net Cash Flow:
$19.98B
1W Performance:
-1.89%
1M Performance:
-0.91%
6M Performance:
+24.18%
1Y Performance:
+9.63%
1-Day Range:
$257.87
$261.43
1-Week Range:
$257.87
$268.93
52-Week Range:
$190.75
$269.39
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
259.42 | 467.12B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,153.91 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
257.18 | 653.61B | 97.93B | 21.04B | 17.80B | 8.6278 |
MRK
Merck Co Inc
|
142.97 | 367.07B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
140.34 | 276.48B | 54.66B | 13.58B | 16.05B | 7.0171 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Aug-05-26 | Upgrade | Erste Group | Hold → Buy |
| Apr-30-26 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-08-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-10-25 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-04-25 | Downgrade | DZ Bank | Buy → Hold |
| Oct-14-25 | Downgrade | Erste Group | Buy → Hold |
| Oct-01-25 | Downgrade | HSBC Securities | Buy → Hold |
| Sep-17-25 | Upgrade | Berenberg | Hold → Buy |
| Aug-12-25 | Resumed | Piper Sandler | Overweight |
| Aug-07-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
AbbVie's Rinvoq Shows Promise in Vitiligo Trials, ABBV Stock Hig - GuruFocus
AbbVie long-term data buoys Rinvoq for vitiligo - Seeking Alpha
AbbVie Presents Long-Term RINVOQ® Data Showing Continued Repigmentation in Non-Segmental Vitiligo - Investing News Network
Why Is AbbVie (NYSE:ABBV) Suddenly a Must-Watch Healthcare Stocks Stock Today? - kalkinemedia.com
AbbVie to Host Third-Quarter 2026 Earnings Conference Call - Investing News Network
AbbVie to release Q3 2026 earnings on Oct 30 be... - Pluang
AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It - uk.finance.yahoo.com
ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell? - Zacks Investment Research
AbbVie stock pre-market at EUR 231.40: minus 0.09 percent - AD HOC NEWS
New report explores the future of aesthetic treatments - kutv.com
AbbVie Stock: Buy, Sell, or Hold in October? - theglobeandmail.com
AbbVie’s eczema drug shows benefit in Phase 2; BioMarin lays off 117 - Endpoints News
AbbVie Reveals Positive Data for Eczema and Weight Loss Candidates - Benzinga
AbbVie unveils promising results for its obesity drug candidate - marketscreener.com
BofA Boosts AbbVie and J&J Price Targets on Growth and Pipeline Strength - AOL.com
AbbVie (ABBV) Reports Promising Phase 1 Weight Loss Data for ABB - GuruFocus
AbbVie's ABBV-295 delivers up to 9.8% weight loss in Phase 1 (ABBV:NYSE) - Seeking Alpha
AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026 - Investing News Network
AbbVie's Zumilokibart Phase 2 Success Highlights Dividend Sustai - GuruFocus
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress - Investing News Network
At 16 weeks, all three doses of AbbVie’s eczema treatment improved skin more than placebo. - Stock Titan
AbbVie reports positive phase 2 data for Zumilokibart in atopic dermatitis - Seeking Alpha
Three late-breaking reports will be part of AbbVie's 60 research presentations on skin diseases. - Stock Titan
AbbVie Inc (ABBV) Stock Down 1.1% but Still Overvalued -- GF Sco - GuruFocus
Enterprise value of AbbVie, Inc. – HAN:4AB - TradingView
If You Invested $1000 In AbbVie Stock 10 Years Ago, You Would Have This Much Today - Benzinga
AbbVie (ABBV) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo! Finance Canada
AbbVie Inc. stock outperforms competitors despite losses on the day - MarketWatch
Valkai Partners with Abbvie to Apply Advanced Ai Across Targeted Areas of Clinical Development - marketscreener.com
Defensive Dividends: 3 Companies Investors Can Rely On - TradingView
AbbVie (NYSE:ABBV) Wins Juvmo Approval for Parkinson's Disease - kalkinemedia.com
AbbVie Stock Drops Although Juvmo Wins Parkinson's Approval - TradingView
AbbVie Shows Pipeline-Driven Upside Beyond Core Immunology Franchise, BofA Says - Yahoo Finance
AbbVie Wins FDA Nod for New Parkinson's Disease Drug Juvmo - Yahoo Finance
AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development - Investing News Network
UnitedHealth, AbbVie And A Health Care Stock On CNBC’s ‘Final Trades’ - Benzinga
Ginkgo Datapoints, Apheris, AbbVie, and Others Form Antibody Developability Consortium - marketscreener.com
AbbVie partners with Valkai to boost AI in clin... - Pluang
Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium - Yahoo Finance
Is AbbVie (ABBV) A Bargain After FDA Approval Of JUVMO For Parkinson's? - Yahoo Finance
FDA Approves AbbVie's Juvmo for Parkinson Disease - Drug Topics
Can AbbVie’s Backing Help ADARx Win Over Biotech IPO Investors at a $1.74 Billion Valuation? - Yahoo Finance
AbbVie gets FDA approval for Parkinson’s disease drug Juvmo - Investing.com
AbbVie's Tavapadon Wins FDA Nod as First D1/D5 Agonist for Parkinson's - finance.biggo.com
AbbVie’s New Parkinson’s Pill Could Become a Billion-Dollar Drug, Analyst Says - Benzinga
AbbVie Wins FDA Approval for Parkinson’s Drug JUVMO - grafa.com
AbbVie Won FDA Approval for Parkinson’s Pill Juvmo. Here’s Why Management Already Expects a Slow Start - TIKR.com
AbbVie Receives FDA Approval for Parkinson’s Disease Drug Juvmo - Yahoo Finance
AbbVie (ABBV) Gains FDA Approval for Juvmo, Bolstering Parkinson's Portfolio - GuruFocus
U.S. FDA Approves AbbVie's JUVMO for Parkinson's Disease - Investing News Network
AbbVie Inc. (1ABBV.MI) stock price, news, quote and history - Yahoo Finance Singapore
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):